Clinical trial shows immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Science Daily13h
Combination approach shows promise for treating rare, aggressive cancers
A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...
News Medical on MSN16h
New treatment combination improves outcomes for small cell bladder and prostate cancer patients
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
The Lancet13h
Perioperative immunotherapy in soft tissue sarcomas
Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.